Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2136 - Phase III study of atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with treatment-naive advanced, recurrent or metastatic NSCLC unsuitable for platinum (plat)-based chemo

Date

09 Sep 2017

Session

Poster display session

Presenters

Siow Ming Lee

Citation

Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380

Authors

S.M. Lee1, C. Schulz2, A. Cardona3, P. Bartakova4, S. Peters5

Author affiliations

  • 1 Department Of Oncology, UCLH/UCL Cancer Institute/Cancer Research UK Lung Cancer Centre of Excellence, NW1 2PG - London/GB
  • 2 Department Of Internal Medicine Ii, University Hospital Regensburg, Regensburg/DE
  • 3 Pdma Biometrics, F. Hoffmann-La Roche Ltd., Basel/CH
  • 4 Global Product Development Medical Affairs (oncology), F. Hoffmann-La Roche Ltd., Basel/CH
  • 5 Oncology, Centre Hospitalier Universitaire Vaudois, 1011 - Lausanne/CH
More

Resources

Abstract 2136

Background

Most pts with newly diagnosed NSCLC have locally advanced or metastatic disease, with 30%-40% having poor performance status (ECOG PS ≥ 2) due to disease burden and comorbidities. These pts have poor prognosis vs pts with PS 

Trial design

Eligible pts have Stage IIIB/IV NSCLC; are considered unsuitable for plat-based chemo due to poor PS (ECOG PS 2-3); have substantial comorbidities or contraindications for plat-based doublet chemo; have measurable disease; have no EGFR/ALK mutations and have received no prior systemic therapy. Pts will be randomized 2:1 to receive atezo 1200 mg IV q3w or single-agent chemo (vin [PO/IV], gem [IV]) per local practice until PD. Pts on atezo may continue therapy until loss of clinical benefit. Stratification factors include histology subtype (squamous vs nonsquamous), PD-L1 status (by VENTANA SP142 IHC assay) and presence of brain metastases. Primary endpoint is OS. Secondary endpoints include OS at 6, 12, 18 and 24 mo; ORR; PFS; DOR and safety. Tumor biopsies and blood samples (pre-treatment all mandatory; at PD only blood mandatory) will be assessed for biomarkers associated with atezo responses and immune escape. Planned enrollment is ≈ 441 pts.

Clinical trial identification

NCT pending (available on poster)

Legal entity responsible for the study

F. Hoffmann-La Roche Ltd.

Funding

F. Hoffmann-La Roche Ltd.

Disclosure

S.M. Lee: Advisory Board for Roche, Merck, Bristol‐Myers, Astra Zeneca. C. Schulz: Scientific Advisor or Membership: AstraZeneca, BMS, Boehringer, Lilly, Novartis, Roche Honoraria: AstraZeneca, Celgene, BMS, Boehringer, Lilly, Novartis, Roche. A. Cardona: Roche employee. P. Bartakova: F. Hoffmann-La Roche employee and company stock ownership. S. Peters: Edu grants, consultation, AB, lectures: Amgen, AZ, BI, BMS, Clovis, Eli Lilly, F. Hoffmann-La Roche, Guardant health, Janssen, Merck Sharp and Dohme, and Merck Serono, Merrimack, Morphotek, Pfizer, Regeneron, Takeda.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.